BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for scarring and other fibrosis-related disorders and autoimmune therapeutics, today ...
Non-Cystic Fibrosis Bronchiectasis Treatment Market to Reach USD 3.5 Bn by 2035 at 5.8% CAGR, Driven by rising disease burden ...
Researchers at the University of Arizona uncovered a previously unknown population of circulating immune cells that play a critical role in fibrosis, the buildup of scar tissue that can lead to organ ...
Researchers at the University of Arizona have uncovered a previously unknown population of circulating immune cells that play ...
The U.S. FDA cleared 20 drugs in October 2025, up from 17 in September, 18 in August and 17 in July, bringing the year’s total to 181 approvals through the first 10 months. Two new molecular entities ...
United Therapeutics' stock surged after IPF trial results and what future pivotal trials could mean for investors. See here ...
Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...
The Pulmonary Fibrosis Foundation (PFF) today announced a new five-year strategic plan, The PFF is ME, a community-driven roadmap shaped by input from more than 350 people affected by pulmonary ...
-Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel mechanism of action for treating the underlying ...
ACEi therapy initiated in the 5 years prior to IPF diagnosis was independently linked to lower all-cause mortality, suggesting ACEi might act as a disease-modifying agent. Angiotensin-converting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback